Market Summary
USD49.69+1.39
Delayedas of 20 Sep 2023, 12:32 pm2.88%
APLS Stock Price
APLS RSI Chart
APLS Valuation
APLS Price/Sales (Trailing)
APLS Profitability
APLS Fundamentals
APLS Revenue
APLS Earnings
Price Action
52 Week Range
19.8394.75
(Low)(High)
Last 7 days
14.4%
Last 30 days
57.6%
Last 90 days
-44.8%
Trailing 12 Months
-24.3%
APLS Financial Health
APLS Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for APLS
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-15 | Machiels Alec | sold | -56,675 | 45.34 | -1,250 | - |
2023-09-15 | Machiels Alec | acquired | 3,337 | 2.67 | 1,250 | - |
2023-09-14 | Chopas James George | acquired | - | - | 2,500 | vp/chief accounting officer |
2023-09-08 | Deschatelets Pascal | acquired | 49,395 | 2.67 | 18,500 | chief scientific officer |
2023-09-08 | Deschatelets Pascal | sold | -514,440 | 42.87 | -12,000 | chief scientific officer |
2023-09-06 | SCHEIBLER LUKAS | sold | -75,525 | 43.01 | -1,756 | chief research officer |
2023-09-01 | Francois Cedric | sold | -6,262,960 | 41.7531 | -150,000 | chief executive officer |
2023-09-01 | Francois Cedric | acquired | 801,000 | 2.67 | 300,000 | chief executive officer |
2023-08-31 | Chopas James George | sold | -22,715 | 41.226 | -551 | vp/chief accounting officer |
2023-08-08 | Deschatelets Pascal | acquired | 49,395 | 2.67 | 18,500 | chief scientific officer |
Which funds bought or sold APLS recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-12 | Farther Finance Advisors, LLC | unchanged | - | 327 | 1,184 | -% |
2023-08-24 | Alberta Investment Management Corp | sold off | -100 | -264,829 | - | -% |
2023-08-24 | PERCEPTIVE ADVISORS LLC | added | 46.22 | 37,346,100 | 73,976,600 | 2.14% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | reduced | -37.04 | -92,888 | 619,480 | 0.01% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -65.1 | -486,438 | 452,409 | -% |
2023-08-21 | Affinity Asset Advisors, LLC | reduced | -71.43 | -1,397,600 | 911,000 | 0.32% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | reduced | -57.25 | -1,479,000 | 2,131,000 | 0.02% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -7.21 | 2,091,470 | 9,518,770 | 0.01% |
2023-08-18 | Legato Capital Management LLC | added | 27.31 | 348,180 | 807,328 | 0.11% |
2023-08-17 | Orion Portfolio Solutions, LLC | reduced | -3.71 | 377,064 | 1,519,820 | 0.02% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Apellis Pharmaceuticals
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Sep 08, 2023 | wellington management group llp | 12.55% | 14,770,859 | SC 13G/A | |
| Jul 18, 2023 | ecor1 capital, llc | 5.4% | 6,307,547 | SC 13G | |
| Jul 07, 2023 | blackrock inc. | 4.9% | 5,747,184 | SC 13G/A | |
| Feb 14, 2023 | t. rowe price investment management, inc. | 5.3% | 5,842,660 | SC 13G | |
| Feb 14, 2023 | avoro capital advisors llc | 9.6% | 10,625,000 | SC 13G/A | |
| Feb 14, 2023 | price t rowe associates inc /md/ | 2.5% | 2,749,542 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 8.33% | 9,212,491 | SC 13G/A | |
| Feb 06, 2023 | wellington management group llp | 7.98% | 8,820,398 | SC 13G/A | |
| Feb 01, 2023 | blackrock inc. | 7.0% | 7,704,194 | SC 13G/A | |
| Feb 14, 2022 | morningside venture investments ltd | 13.2% | 12,806,342 | SC 13G/A |
Recent SEC filings of Apellis Pharmaceuticals
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 19, 2023 | 4 | Insider Trading | |
| Sep 19, 2023 | 4 | Insider Trading | |
| Sep 18, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 18, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 18, 2023 | 4 | Insider Trading | |
| Sep 18, 2023 | 4 | Insider Trading | |
| Sep 15, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 11, 2023 | 4 | Insider Trading | |
| Sep 08, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 08, 2023 | SC 13G/A | Major Ownership Report |
Peers (Alternatives to Apellis Pharmaceuticals)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
BGNE | 287.4B | 1.8B | 8.19% | 34.91% | -165.92 | 158.74 | 69.45% | 14.65% |
ABBV | 271.2B | 56.0B | 2.23% | 8.69% | 31.23 | 4.84 | -2.31% | -31.27% |
VRTX | 92.4B | 9.5B | 3.90% | 25.64% | 27.45 | 9.72 | 13.83% | 5.33% |
REGN | 89.5B | 12.7B | 3.00% | 16.97% | 20.83 | 7.07 | -10.94% | -24.40% |
ALNY | 21.9B | 1.2B | -5.57% | -18.68% | -20.63 | 17.73 | 39.94% | -8.44% |
SRPT | 11.1B | 1.0B | 6.45% | 3.35% | -12.24 | 11.07 | 20.15% | -79.16% |
UTHR | 10.4B | 2.1B | -3.97% | 1.74% | 11.88 | 4.9 | 18.01% | 38.16% |
| MID-CAP | ||||||||
MDGL | 3.1B | - | -5.78% | 157.92% | -9.48 | - | - | -28.88% |
BPMC | 3.1B | 225.6M | 4.14% | -26.79% | -5.62 | 13.8 | -2.11% | 21.02% |
RARE | 2.6B | 402.9M | 3.70% | -20.53% | -3.61 | 6.46 | 20.50% | -42.46% |
MRTX | 1.9B | 27.2M | -16.17% | -58.23% | -2.56 | 69.33 | - | -14.43% |
| SMALL-CAP | ||||||||
CYTK | 3.1B | - | 1.51% | -37.05% | -7.31 | 33.28 | 34.30% | -149.91% |
CPRX | 1.4B | 302.9M | -11.98% | -2.00% | 11.71 | 4.47 | 77.72% | 112.02% |
MGNX | 283.7M | 152.5M | -7.29% | 31.99% | 38.08 | 1.86 | 127.84% | 103.41% |
CRBP | 30.6M | - | -1.14% | 3544.51% | -0.66 | - | - | -31.51% |
Apellis Pharmaceuticals News
Returns for APLS
Cumulative Returns on APLS
19.3%
5-Year Cumulative Returns
14.0%
3-Year Cumulative Returns
Risks for APLS
What is the probability of a big loss on APLS?
100%
Probability that Apellis Pharmaceuticals stock will be more than 20% underwater in next one year
74.6%
Probability that Apellis Pharmaceuticals stock will be more than 30% underwater in next one year.
55.4%
Probability that Apellis Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does APLS drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Apellis Pharmaceuticals was unfortunately bought at previous high price.
Drawdowns
Financials for Apellis Pharmaceuticals
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 74.3% | 184,534,000 | 105,887,000 | 75,422,000 | 113,049,000 | 96,643,000 | 80,944,000 | 66,563,000 | 112,583,750 | 158,604,500 | 204,625,250 | 250,646,000 | 128,383,390 | 6,120,779 | 6,516,779 | 5,108,779 | 5,121,814 | 4,638,239 | 4,004,904 | 2,960,771 | 2,728,655 | 2,376,132 |
| Operating Expenses | 6.8% | 797,049,000 | 746,585,000 | 670,035,000 | 633,013,000 | 591,664,000 | 621,628,000 | 602,840,000 | 573,025,000 | 569,578,000 | 490,176,000 | 464,372,000 | 468,861,333 | 388,528,000 | - | 288,015,000 | 279,792,000 | - | - | 127,925,000 | - | - |
| S&GA Expenses | 14.7% | 376,240,000 | 328,070,000 | 277,163,000 | 234,258,000 | 201,615,000 | 187,379,000 | 176,771,000 | 179,801,000 | 171,029,000 | 150,476,000 | 139,401,000 | 122,377,000 | 104,015,000 | 88,379,000 | 67,046,000 | 45,968,797 | 33,604,922 | 26,774,745 | 22,639,000 | 21,108,164 | 16,914,476 |
| R&D Expenses | -1.5% | 400,315,000 | 406,318,000 | 387,236,000 | 365,994,000 | 358,520,000 | 352,802,000 | 345,869,000 | 318,025,000 | 323,499,000 | 314,650,000 | 299,921,000 | 328,055,000 | 286,167,000 | 249,771,000 | 220,969,000 | 173,303,035 | 151,523,491 | 128,363,110 | 105,286,000 | 87,612,818 | 67,591,244 |
| EBITDA | 100.0% | - | -686,390,000 | -644,948,000 | -625,082,000 | -628,220,000 | -705,630,000 | -734,358,000 | -794,162,000 | -788,526,000 | -327,036,000 | -330,100,000 | -291,749,994 | -300,619,473 | -300,479,000 | -303,720,000 | - | - | - | - | - | - |
| EBITDA Margin | 100.0% | - | -6.48 | -8.55 | -5.53 | -6.50 | -8.65 | -11.03 | -7.05 | -4.97 | -1.60 | -1.32 | -2.27 | -49.12 | -46.11 | -59.45 | - | - | - | - | - | - |
| Interest Expenses | 0% | 3,286,000 | 3,286,000 | 5,003,000 | 5,003,000 | 6,732,000 | 6,732,000 | 10,265,000 | 10,265,000 | 15,993,000 | 15,993,000 | 12,929,000 | 12,957,000 | 4,088,000 | 4,228,000 | 987,000 | 1,436,306 | 1,535,722 | 1,852,250 | 1,816,000 | 1,338,694 | 1,344,371 |
| Earnings Before Taxes | 4.9% | -657,624,000 | -691,272,000 | -651,503,000 | -631,622,000 | -636,370,000 | -700,070,000 | -746,002,000 | -797,894,666 | -805,700,000 | -734,636,000 | -343,029,000 | - | - | - | -304,707,000 | - | - | - | -127,502,000 | - | - |
| EBT Margin | 100.0% | - | -6.53 | -8.64 | -5.59 | -6.58 | -8.75 | -11.21 | -7.16 | -5.08 | -1.68 | -1.37 | -2.37 | -49.79 | -46.76 | -59.64 | - | - | - | - | - | - |
| Net Income | 4.9% | -657,075,000 | -691,015,000 | -652,172,000 | -634,114,000 | -638,416,000 | -701,630,000 | -746,354,000 | -520,156,000 | -460,285,000 | -359,711,000 | -344,874,000 | -536,357,000 | -470,482,000 | -422,955,000 | -304,707,000 | -227,948,475 | -194,095,590 | -156,339,890 | -127,502,194 | -109,298,615 | -84,899,773 |
| Net Income Margin | 100.0% | - | -6.53 | -8.65 | -5.61 | -6.61 | -8.60 | -11.21 | -4.62 | -2.90 | -1.76 | -1.38 | -4.18 | -76.87 | -64.90 | -59.64 | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -581,502,000 | -515,269,000 | -486,192,000 | -500,556,000 | -522,077,000 | -564,229,000 | -310,443,000 | -245,028,000 | -210,924,000 | -165,910,000 | -389,404,238 | -339,910,389 | -285,176,516 | -212,828,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -6.5% | 916 | 979 | 760 | 873 | 1,002 | 1,146 | 882 | 526 | 700 | 810 | 961 | 768 | 870 | 689 | 389 | 466 | 317 | 318 | 204 | 239 | 267 |
| Current Assets | -6.5% | 893 | 954 | 720 | 832 | 960 | 1,104 | 824 | 475 | 655 | 774 | 917 | 742 | 854 | 672 | 373 | 451 | 308 | 311 | 202 | 239 | 267 |
| Cash Equivalents | -19.5% | 616 | 765 | 552 | 584 | 604 | 633 | 642 | 284 | 271 | 265 | 566 | 416 | 317 | 418 | 352 | 434 | 289 | 288 | 176 | 221 | 254 |
| Inventory | 20.7% | 103 | 85.00 | 86.00 | 60.00 | 48.00 | 33.00 | 16.00 | 2.00 | 4.00 | - | - | - | - | - | - | - | - | - | - | - | - |
| Net PPE | -10.5% | 5.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | - | - |
| Liabilities | 0.6% | 570 | 567 | 590 | 565 | 668 | 684 | 683 | 583 | 841 | 758 | 756 | 662 | 638 | 430 | 355 | 327 | 158 | 94.00 | 43.00 | 43.00 | 37.00 |
| Current Liabilities | 26.1% | 175 | 139 | 168 | 115 | 127 | 125 | 132 | 94.00 | 158 | 84.00 | 128 | 75.00 | 58.00 | 51.00 | 66.00 | 45.00 | 36.00 | 20.00 | 17.00 | 16.00 | 10.00 |
| Shareholder's Equity | -16.2% | 345 | 412 | 170 | 307 | 334 | 462 | 199 | - | - | 52.00 | 205 | 106 | 232 | 259 | 34.00 | 140 | 159 | 225 | 161 | 196 | 230 |
| Retained Earnings | -4.9% | -2,608 | -2,486 | -2,308 | -2,142 | -1,951 | -1,795 | -1,656 | -1,508 | -1,313 | -1,093 | -926 | -1,004 | -868 | -750 | -581 | -468 | -398 | -327 | -276 | -240 | -204 |
| Additional Paid-In Capital | 1.9% | 2,955 | 2,900 | 2,480 | 2,453 | 2,289 | 2,260 | 1,857 | 1,453 | 1,174 | 1,147 | 1,131 | 1,112 | 1,101 | 1,008 | 616 | 608 | 558 | 552 | 438 | 436 | 434 |
| Shares Outstanding | 1.2% | 118 | 116 | 111 | 110 | 107 | 106 | 98.00 | 87.00 | 81.00 | 79.00 | 76.00 | 75.00 | 75.00 | 74.00 | 62.00 | 64.00 | 64.00 | 63.00 | 54.00 | 54.00 | 55.00 |
Cashflow (Last 12 Months)
| Cashflow (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -7.4% | -622,936,000 | -579,805,000 | -513,745,000 | -485,500,000 | -499,708,000 | -521,372,000 | -563,126,000 | -308,648,000 | -239,847,000 | -205,453,000 | -160,488,000 | -384,538,000 | -338,311,000 | -283,924,000 | -211,135,000 | -173,542,426 | -153,077,874 | -143,865,751 | -131,241,000 | -102,295,378 | -80,300,798 |
| Share Based Compensation | 6.8% | 105,883,000 | 99,135,000 | 91,085,000 | 86,156,000 | 79,809,000 | 75,001,000 | 70,667,000 | 63,849,000 | 58,754,000 | 52,521,000 | 45,376,000 | 39,989,000 | 33,185,000 | 25,879,000 | 21,144,000 | 15,865,361 | 12,621,285 | 10,681,812 | 7,733,000 | 10,068,979 | 8,563,592 |
| Cashflow From Investing | -25.1% | 248,282,000 | 331,583,000 | 59,893,000 | 20,744,000 | 75,609,000 | 122,432,000 | 247,616,000 | 162,545,000 | 181,659,000 | -235,900,000 | -316,989,000 | -317,053,000 | -516,287,000 | -228,672,000 | -1,693,000 | -2,050,666 | -2,134,000 | -3,500,000 | - | - | - |
| Cashflow From Financing | 1.7% | 386,356,000 | 380,061,000 | 365,659,000 | 765,563,000 | 758,047,000 | 767,308,000 | 392,236,000 | 14,595,000 | 13,401,000 | 290,543,000 | 692,178,000 | 686,070,000 | 884,094,000 | 643,390,000 | 388,541,000 | 388,447,297 | 189,458,863 | 280,098,303 | 131,903,000 | 309,828,188 | 413,155,496 |
APLS Income Statement
2023-06-30Condensed Consolidated Statements of Operations and Comprehensive Income/(Loss) (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenue: | ||||
| Revenue | $ 94,969 | $ 16,322 | $ 139,814 | $ 30,703 |
| Operating expenses: | ||||
| Cost of sales | 8,379 | 82 | 16,188 | 1,329 |
| Research and development | 95,658 | 101,661 | 205,684 | 192,606 |
| General and administrative | 111,373 | 63,203 | 213,466 | 114,390 |
| Total operating expenses: | 215,410 | 164,946 | 435,338 | 308,325 |
| Net operating loss | (120,441) | (148,624) | (295,524) | (277,622) |
| Interest income | 6,002 | 1,432 | 11,395 | 1,530 |
| Interest expense | (7,341) | (8,448) | (14,869) | (16,986) |
| Other (expense)/income, net | (63) | 149 | (341) | (140) |
| Net loss before taxes | (121,843) | (155,491) | (299,339) | (293,218) |
| Income tax expense | 194 | 486 | 476 | 1,694 |
| Net loss | (122,037) | (155,977) | (299,815) | (294,912) |
| Other comprehensive gain/(loss): | ||||
| Unrealized gain/(loss) on marketable securities | (766) | (818) | ||
| Foreign currency gain | (21) | (369) | 79 | (286) |
| Total other comprehensive income/(loss) | (21) | (1,135) | 79 | (1,104) |
| Comprehensive loss, net of tax | $ (122,058) | $ (157,112) | $ (299,736) | $ (296,016) |
| Net loss per common share, basic | $ (1.02) | $ (1.46) | $ (2.57) | $ (2.88) |
| Net loss per common share, diluted | $ (1.02) | $ (1.46) | $ (2.57) | $ (2.88) |
| Weighted-average number of common shares used in net loss per common share, basic | 119,316 | 106,630 | 116,594 | 102,349 |
| Weighted-average number of common shares used in net loss per common share, diluted | 119,316 | 106,630 | 116,594 | 102,349 |
| Product Revenue, Net [Member] | ||||
| Revenue: | ||||
| Revenue | $ 89,645 | $ 15,654 | $ 128,444 | $ 27,763 |
| Licensing and other revenue [Member] | ||||
| Revenue: | ||||
| Revenue | $ 5,324 | $ 668 | $ 11,370 | $ 2,940 |
APLS Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 616,259 | $ 551,801 |
| Accounts receivable | 110,913 | 7,727 |
| Inventory | 103,216 | 85,714 |
| Prepaid assets | 34,404 | 36,350 |
| Restricted cash | 1,085 | 1,273 |
| Other current assets | 26,809 | 36,658 |
| Total current assets | 892,686 | 719,523 |
| Non-current assets: | ||
| Right-of-use assets | 16,726 | 18,747 |
| Property and equipment, net | 5,339 | 6,148 |
| Other assets | 827 | 15,799 |
| Total assets | 915,578 | 760,217 |
| Current liabilities: | ||
| Accounts payable | 27,500 | 37,342 |
| Accrued expenses | 97,716 | 95,139 |
| Current portion of development liability | 43,769 | 29,504 |
| Current portion of right-of-use liabilities | 5,852 | 5,625 |
| Total current liabilities | 174,837 | 167,610 |
| Long-term liabilities: | ||
| Long-term development liability | 289,960 | 315,647 |
| Convertible senior notes | 92,883 | 92,736 |
| Right-of-use liabilities | 12,066 | 14,352 |
| Other liabilities | 429 | |
| Total liabilities | 570,175 | 590,345 |
| Stockholders' equity: | ||
| Preferred stock, $0.0001 par value; 10,000 shares authorized, and zero shares issued and outstanding at June 30, 2023 and December 31, 2022 | 0 | 0 |
| Common stock, $0.0001 par value; 200,000 shares authorized at June 30, 2023 and December 31, 2022; 117,579 shares issued and outstanding at June 30, 2023, and 110,772 shares issued and outstanding at December 31, 2022 | 12 | 11 |
| Additional paid-in capital | 2,954,862 | 2,479,596 |
| Accumulated other comprehensive loss | (796) | (875) |
| Accumulated deficit | (2,608,675) | (2,308,860) |
| Total stockholders' equity | 345,403 | 169,872 |
| Total liabilities and stockholders' equity | $ 915,578 | $ 760,217 |
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.